Comentários
Escrever um comentário-
Comentário de Nicole Kucharowski
- Publicado
- Licença
- CC BY 4.0
Major Points
We appreciate the reviewer’s suggestion to apply Dilp2 antibody staining and to analyze Golgi-peroxisome contacts across multiple peroxisome biogenesis mutant backgrounds. However, two main points need clarification. First, our manuscript does not claim that Dilp2 accumulates within peroxisomes at the Golgi; rather, we propose that Golgi-peroxisome proximity facilitates efficient secretion of insulin-like peptides, not their storage in peroxisomes. Therefore, antibody-based detection of Dilp2 in peroxisomes would not test the hypothesis we put forward. Second, there are no peroxisomes present in pex19 or pex3 mutant backgrounds, so it is technically impossible to assess Golgi-peroxisome contacts or Dilp2 localization to peroxisomes in these animals. This limitation applies to all experiments aiming to visualize peroxisome-associated phenomena in these genetic contexts. Therefore, our current data integrate both structural and functional approaches to support the role of Golgi-peroxisome proximity in peptide secretion, while explicitly leaving room for future work to dissect mechanistic detail.
We thank the reviewer for raising the important point of reagent validation. The RNAi lines used in this study were obtained from established community resources (VDRC, BDSC) where design minimizes off-target effects and in several cases, we employed more than one independent RNAi line or combined RNAi with mutant alleles to confirm phenotypes. For antibodies, all used reagents are either validated in previous publications (Li et al., 2015 Nature) or functionally validated in this work by showing loss of signal upon knockdown or mutation. For example, the antibody against PMP70 showed specific loss of staining in respective mutant backgrounds (Line 265), providing strong evidence of reagent specificity and efficacy. Importantly, the consistency of our findings across independent reagents provides confidence that the reported phenotypes reflect specific gene functions rather than off-target effects.
We thank the reviewers for raising this point. The behavior of control animals under nutritional manipulation has been well characterized by Bisen et al. (eLife 2024), who show that IPC activity decreases upon starvation and normalizes upon refeeding. Our results are fully consistent with these published controls, and we have cited this work in the Results section (Line 182). Importantly, our novel finding is that pex19 mutants maintain this nutritional state-dependent modulation of IPC activity but nevertheless fail to release neuropeptides, thereby uncoupling activity from secretion. This extends the published control framework and provides new mechanistic insight into the role of peroxisomes in peptide secretion.
Minor Points
We will revise the figure legend to explicitly state that the image shows Dilp2 antibody staining, not a transgene.
We will expand the schematic and legend to clarify the sequence of peroxisome biogenesis factors: Pex19/3/16 act early during membrane formation, whereas Pex2/1 function in matrix import.
We appreciate the reviewers insightful point regarding the route of Dilp2 secretion. The assay we employed is an established and widely used readout for insulin release in Drosophila (Ziegler A. et al., Scientific Reports 2018). This approach provides a robust and reproducible measure of relative secretion dynamics, since depletion of somatic Dilp2 stores strongly correlates with regulated release. We fully agree that secretion of Dilp2 physiologically occurs predominantly from axon terminals into the hemolymph, rather than directly from the soma. The somatic signal therefore reflects the mobilization and trafficking of the peptide toward secretory sites, and its loss has been consistently interpreted in the field as a proxy for secretion. To further strengthen our study, in a revised version of the manuscript we will include complementary data demonstrating Dilp2 levels in the hemolymph.
We will correct the citation to refer to Figure 1C instead of Figure 2C.
We thank the reviewer for this observation. The more robust rescue of survival with hemocyte-specific (hml-Gal4) Pex19 reconstitution compared to IPC-specific rescue likely reflects the broader systemic roles of hemocytes in fly physiology. Hemocytes not only participate in immune responses but also regulate metabolism, clear damaged cells, and secrete signaling molecules (Hersperger F. et al., eLife 2023, Bland M.L. Semin Cell Dev Biol. 2023). Restoring Pex19 in these cells can alleviate systemic metabolic imbalances, reduce toxic metabolites such as ROS and free fatty acids and improve overall survival. In contrast, IPC-specific rescue primarily restores Dilp2 secretion, addressing neuroendocrine defects but having limited effect on widespread metabolic dysfunction. It is, in fact, quite surprising that the IPC rescue alone leads to significant improvement in survival. This suggests a systemic effect of restoring peroxisome function only in these neuroendocrine cells. Our data imply that targeted restoration of peroxisome activity within IPCs can exert indirect whole-organism effects, possibly through improved insulin signaling, which is central to metabolic regulation. Thus, the stronger survival benefit from hemocyte rescue likely arises from non-cell-autonomous, systemic improvements beyond the neuroendocrine axis, while the IPC rescue result points to interesting global physiological consequences from correcting this pathway merely in IPCs.
We thank the reviewer for the suggestion to clarify terminology. By “depletion of peroxisomes”, we refer to loss of functional peroxisomal membranes and failure to import matrix proteins, both essential for peroxisome biogenesis. Matrix proteins are soluble luminal enzymes imported via PTS1/PTS2 signals. “Ghosts” are membrane remnants lacking matrix proteins, seen when matrix import factors (e.g., Pex2) are disrupted, whereas loss of membrane biogenesis factors (Pex3/16/19) eliminates detectable peroxisomal membranes entirely. This distinction is key, as disruption of membrane factors impairs Dilp2 secretion, while matrix import defects do not, consistent with the residual “ghosts” supporting partial function. We will revise the text to define these terms clearly.
We will remove the redundant panel from the supplement to avoid confusion.
We thank the reviewer for raising this point. BODIPY-Ceramide is a well-established fluorescent shingolipid analog whose localization is dynamic and context-dependent. It is initially taken up and accumulates in the Golgi, supporting its common use as a Golgi marker (Pagano et al., 1991). Over time, it can traffic to other membranes, including the plasma membrane and endosomes (Marks D.L. 2008). Thus, Golgi labeling reflects early uptake while plasma membrane labeling corresponds to later trafficking. We will clarify this dynamic distribution in the revised text. Furthermore, we will provide an unsaturated version of Figure 4E in the supplement.
We thank the reviewer for raising this point. We will test Dilp2 release in px-mCherry and other Golgi marker backgrounds to ensure these tools do not perturb Golgi-peroxisome interactions. We will include these data in the supplement.
We will implement a consistent color scheme across all panels (Golgi vs. peroxisomes) and add individual legends for clarity.
We will quantify Golgi size across feeding states. If significant changes are observed, we will include them in the manuscript; if not, we will state that explicitly and provide the quantification in the supplement.
We will add a brief explanation: “BioGRID is an open-source database of protein and genetic interactions; we used it to identify potential Golgi-peroxisome contact regulators.”
We thank the reviewer for raising this point. GM130 is not a luminal peroxisomal matrix protein but a peripheral membrane protein bound to the cytoplasmic face of the cis-Golgi (Nakamura et al., 1995, Barr et al., 1998). Our use of “matrix protein” referred to its structural role within the Golgi matrix scaffold, not to soluble luminal proteins. The accumulation observed in pex19 mutants therefore reflects mislocalization of a Golgi-associated protein rather than a peroxisomal matrix protein. To avoid confusion, we will revise the text to refer to GM130 as a “Golgi scaffold” or “Golgi peripheral membrane protein”.
We thank the reviewer for this important point. While DCVs are classically reported as ~100-150 nm in diameter, our use of a 500 nm threshold reflects both technical and biological considerations. Confocal resolution (~200-300 nm laterally, worse axially) limits reliable detection of smaller vesicles and vesicle clusters often appear as single, larger objects after 3D segmentation. In addition, DCV size is not fixed but varies with cell type, developmental stage and cargo load, with larger vesicles and aggregates reported in neuroendocrine cells (Kirchner et al., 2022). Our empirical threshold therefore enabled robust and reproducible identification of vesicle-like structures while minimizing background. Importantly, the objects detected showed appropriate colocalization with secretory markers and correlated with functional readouts, supporting their biological relevance. We will revise the Methods to clarify this rationale.
We will revise the figure legends and text to clarify that Figure 1E illustrates peroxisome maturation (contextual to Dilp2 biology rather than showing Dilp2 directly) and that Figure 6G highlights the relevant pathway.
Disclosure:
Portions of my responses to the reviewer’s major and minor comments were refined with the assistance of OpenAI’s ChatGPT to improve clarity and tone.
Competing interests
The author of this comment declares that they have no competing interests.